Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Efficacy of Adjuvant Immunotherapy With Cytokine-induced Killer Cells in Patients With Stage II/III Colon Cancer

It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients.

The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).

Inclusion Criteria:

• Colon cancer in stage III or stage II with high risk after R0 resection
• Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
• Life expectancy of at least 3 months;
• Normal bone marrow, liver, renal, heart and lung function;
• Age between 18-80;
• Patients who provided written informed consent for this study

Exclusion Criteria:

• With uncontrolled other malignant tumors;
• With uncontrolled infection or tubercle bacillus (TB) or underlying diseases that were severe or life threatening;
• Patients who need to treat with radiotherapy;
• Patients who accepted other immunotherapy
• With sever mental disease or disease with central nervous system (CNS);
• With the history of organ transplantation, including bone marrow transplantation or stem cell transplantation;
• Patients with auto immune diseases;
• pregnant or lactating.